John Michael Ranola

Dr. John Michael Ranola

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2018 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
JRJohn Michael Ranola
John Michael Ranola
RPRachel Pearlman
Rachel Pearlman
HHHeather Hampel
Heather Hampel
BSBrian H. Shirts
Brian H. Shirts

18 October 2016 in BMC Proceedings
Verified
Journal Article
Open access
PDF file
EBElizabeth Blue
Elizabeth Blue
LBLisa A. Brown
Lisa A. Brown
MCMatthew P. Conomos
Matthew P. Conomos
JKJennifer L. Kirk
Jennifer L. Kirk
ANAlejandro Q. Nato
Alejandro Q. Nato
TTTimothy Thornton
Timothy Thornton
Estimating relationships among subjects in a sample, within family structures or caused by population substructure, is complicated in admixed populations. Inaccurate allele frequencies can bias both kinship estimates and tests for association between subjects and a phenotype. We analyzed the simulated and real family data from Genetic Analysis Workshop 19, and were aware of the simulation model. We found that kinship estimation is more accurate when marker data include common variants whose frequencies are less variable across populations. Estimates of heritability and association vary with age for longitudinally measured traits. Accounting for local ancestry identified different true associations than those identified by a traditional approach. Principal components aid kinship estimation and tests for association, but their utility is influenced by the frequency of the markers used to generate them. Admixed families can provide a powerful resource for detecting disease loci, as well as analytical challenges. Allele frequencies, although difficult to adequately estimate in admixed populations, have a strong impact on the estimation of kinship, ancestry, and association with phenotypes. Approaches that acknowledge population structure in admixed families outperform those which ignore it.

7 April 2022 in Human Mutation
Verified
Journal Article
Closed access
RBRonald W. Buie
Ronald W. Buie
JRJohn Michael Ranola
John Michael Ranola
ACAnnie T. Chen
Annie T. Chen
BSBrian H. Shirts
Brian H. Shirts
Clinical genetic sequencing tests often identify variants of uncertain significance. One source of data that can help classify the pathogenicity of variants is familial cosegregation analysis. Identifying and genotyping relatives for cosegregation analysis can be time consuming and costly. We propose an algorithm that describes a single measure of expected variant information gain from genotyping a single additional relative in a family. Then we explore the performance of this algorithm by comparing actual recruitment strategies used in 35 families who had pursued cosegregation analysis with synthetic pedigrees of possible testing outcomes if the families had pursued an optimized testing strategy instead. For each actual and synthetic pedigree, we calculated the likelihood ratio of pathogenicity as each successive test was added to the pedigree. We analyzed the differences in cosegregation likelihood ratio over time resulting from actual versus optimized testing approaches. Employing the testing strategy indicated by the algorithm would have led to maximal information more rapidly in 30 of the 35 pedigrees (86%). Many clinical and research laboratories are involved in targeted cosegregation analysis. The algorithm we present can facilitate a data driven approach to optimal relative recruitment and genotyping for cosegregation analysis and more efficient variant classification.

16 October 2025 in Genetics in Medicine
Verified
Journal Article
Open access
AGAndrew Giles
Andrew Giles
KZKimberly Zayhowski
Kimberly Zayhowski
MRMaggie Ruderman
Maggie Ruderman
JRJohn Michael Ranola
John Michael Ranola
GVGrace E. VanNoy
Grace E. VanNoy
MTMeghan Towne
Meghan Towne
Race, ethnicity, and ancestry (REA) affect the diagnostic utility of genetic testing. In addition to barriers to accessing genetics services, some non-European REA groups experience decreased diagnostic results and increased uncertain results. Exome sequencing (ES) is a unique genetic test because data can be reanalyzed with new information and variants may be reclassified after the original result. We performed a retrospective review of 10,416 clinical ES cases originally analyzed by Ambry Genetics between 2011 and 2021 with reanalysis events through 2023. The relationship between assigned REA group, ES result, reanalysis and reclassification rates, and reanalysis initiators were analyzed with logistic regression. Reanalyses increased the total diagnostic yield from 21.4% to 25.5%. There were no significant differences in reclassification rate among REA groups. However, the African American and Black group (P = 2.8E-07), the Hispanic and Latino group (P = .0022), and the Asian group (P = .033) were significantly less likely to receive provider-initiated reanalysis compared with the White group. Although reclassification rates were not found to be associated with REA group, not all REA groups had the same access to ES reanalysis. Laboratory-initiated proactive reanalysis can help reduce disparities in ES diagnostic utility by reducing barriers to accessing reanalysis.

1 November 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
KKKristin Kohler
Kristin Kohler
AMAshley Marsh
Ashley Marsh
FHFelicia Hernandez
Felicia Hernandez
CHCarolyn Horton
Carolyn Horton
JRJohn Michael Ranola
John Michael Ranola
MHMichael J Hall
Michael J Hall
Purpose: To characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement. Methods: We retrospectively evaluated 662 unrelated probands undergoing hereditary cancer multigene panel testing (MGPT) with isolated EPCAM full-gene deletions (n = 22), isolated EPCAM 3' deletions (n = 96), contiguous EPCAM full-gene deletions extending into MSH2 (n = 64), contiguous EPCAM 3' deletions extending into MSH2 (n = 116), MSH2 gross deletions (n = 155), and MSH2 nonsense/frameshift (ns/fs) variants (n = 209). Lynch syndrome (LS)–associated cancer prevalence, tumor spectrum, and PREMM5 scores were compared across cohorts. Multivariable logistic regression estimated cancer-specific associations relative to a MGPT-negative reference cohort. Results: Isolated EPCAM full-gene deletions, comprising 18.6% of observed isolated EPCAM deletions, were not significantly associated with LS-associated cancers. The LS-associated cancer prevalence was 13.6% in this cohort, compared with 54.6% with isolated EPCAM 3' deletions and 64.1%-72.2% in MSH2 -involving cohorts ( P < .001). Relative to MGPT-negative individuals, isolated EPCAM 3' deletions were strongly associated with colorectal cancer (odds ratio [OR], 17.59; P < .001) but not endometrial cancer (OR, 0.76; P = .790). MSH2 -involving cohorts demonstrated strong associations with both colorectal (ORs, 8.50-16.03; P < .001) and endometrial cancers (ORs, 17.31-30.47; P < .001). Conclusion: These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM . Expanded detection across the full EPCAM gene and its 3' region distinguishes isolated full-gene deletions, which do not disrupt downstream MSH2 and are not associated with LS phenotypes, from isolated 3' deletions with a colorectal-predominant phenotype, and contiguous EPCAM-MSH2 deletions with an MSH2 -like LS phenotype. Precise delineation of EPCAM deletion boundaries and MSH2 involvement define three clinically relevant risk groups and support more precise risk assessment, counseling, and surveillance.

2 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LCLeslie Clapp
Leslie Clapp
ANArpita Neogi
Arpita Neogi
MTMeghan Towne
Meghan Towne
DDDaniel Dykas
Daniel Dykas
JRJohn Michael Ranola
John Michael Ranola
AMArya Mani
Arya Mani
Introduction: Genetic variants in the Tenascin-XB (TNXB) gene have been associated with autosomal recessive Ehlers-Danlos Syndrome (classical-like) without vascular features. Here, we report the contribution of two TNXB variants, in cis or trans, to the development of arterial aneurysms and bicuspid aortic valves with or without connective tissue disease features present. Methods: The identification of compound heterozygosity in TNXB (c.8791+1G>A, c.12469+2T>C) in a 52-year-old female with fibromuscular dysplasia, bilateral vertebral artery dissections, and thoracic aortic aneurysm by whole exome sequencing (WES) prompted screening for TNXB variants in an institutional WES registry comprising 350 individuals with aneurysms and/or dissections. Multigene panel testing (MGPT) results from 1844 individuals tested at Ambry Genetics for a personal or family history of aneurysms, dissections, or other connective tissue disease features were used for replication analysis. Random exomes of 26,922 unaffected individuals were used as controls. Statistical analysis using Fisher’s exact test was carried out to compare the frequency of two or more TNXB variants in cases vs. controls. AlphaFold3 structural modeling was used to assess the effects of variants in cis on the 3-D structure and molecular interaction with the TGF-beta-3 proprotein. Results: There were significantly higher numbers of individuals who carried two or more rare, nonsynonymous TNXB variants, in cis or trans, in both WES (n=5/350; 1.4%) and MGPT (n=19/1844, 1.0%) datasets (p<0.01) compared to ethnically matched controls (n=89/26922; 0.14%). Additionally, there was a significantly higher prevalence of bicuspid aortic valve (BAV) in the MGPT cohort compared to the general population (11% vs. <2 % reported). The analysis by AlphaFold3 structural modeling revealed increased distortion of the 3-D structure caused by the presence of two variant(s) in cis vs. one variant in TNXB. Conclusion: This data strongly suggests an association between vascular aneurysm and/or dissection or bicuspid aortic valves and individuals with two TNXB variants.